Fexofinadine is most widely used, second generation antihistamine drug for the treatment of allergy symptoms and hay fever.

The company has tied-up for regular supplies of Fexofinadine to one of its top US customers, with which the company has long standing relations lasting over two decades. The company has already supplied validation quantities and the regular commercial supplies would start after approval of validation batches.

Fexofinadine is a very established anti-allergy drug with a market size of around 700MT and expected to give immediate impetus to company's export business.

Morepen is the third largest exporters of this drug to the world and will move up in the ranks after this approval. The export of Fexofenadine to the highly regulated US market is expected to see multi-fold growth resulting in better profitability margins for the company.

The company is having sufficient capacity to service the present demand and is also expanding capacities to become a leading player in the product in the coming years.

Sushil Suri, chairman and managing director stated, “Approval of anti-allergy drug Fexofinadine (Allegra) by USFDA is an important milestone in the company's therapeutic journey since it consolidates Morepen's position in the anti-allergy market with already having USFDA approval for three lead products loratadine, desloratadine and montelukast.

It also cements our long-standing relations with our prime customers who have worked with us for two decades and shows their confidence in company's product quality and delivery”

Morepen Laboratories is a pharmaceutical and healthcare products company. It is a leading manufacturer of high-quality APIs, home diagnostics, formulations and OTC products in north India.

The company's consolidated net profit rose 37.50% to Rs 37.36 crore on a 17.51% increase in net sales to Rs 395.31 crore in Q2 FY22 over Q2 FY21.